Littérature scientifique sur le sujet « Broadly neutralizing antibodies (bNAbs) »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Broadly neutralizing antibodies (bNAbs) ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Broadly neutralizing antibodies (bNAbs)"
Karuna, Shelly T., et Lawrence Corey. « Broadly Neutralizing Antibodies for HIV Prevention ». Annual Review of Medicine 71, no 1 (27 janvier 2020) : 329–46. http://dx.doi.org/10.1146/annurev-med-110118-045506.
Texte intégralYang, Guang, Mengfei Liu, Kevin Wiehe, Nathan Nicely, Barton Haynes, John Mascola, Pamela Bjorkman et Garnett Kelsoe. « HIV broadly neutralizing antibodies and immunological tolerance (VAC7P.988) ». Journal of Immunology 192, no 1_Supplement (1 mai 2014) : 141.33. http://dx.doi.org/10.4049/jimmunol.192.supp.141.33.
Texte intégralLubow, Jay, Lisa M. Levoir, Duncan K. Ralph, Laura Belmont, Maya Contreras, Catiana H. Cartwright-Acar, Caroline Kikawa et al. « Single B cell transcriptomics identifies multiple isotypes of broadly neutralizing antibodies against flaviviruses ». PLOS Pathogens 19, no 10 (9 octobre 2023) : e1011722. http://dx.doi.org/10.1371/journal.ppat.1011722.
Texte intégralSprenger, Kayla G., Joy E. Louveau, Pranav M. Murugan et Arup K. Chakraborty. « Optimizing immunization protocols to elicit broadly neutralizing antibodies ». Proceedings of the National Academy of Sciences 117, no 33 (3 août 2020) : 20077–87. http://dx.doi.org/10.1073/pnas.1919329117.
Texte intégralGlazkova, D. V., E. V. Bogoslovskaya, G. A. Shipulin et S. M. Yudin. « Broadly neutralizing antibodies for the treatment of HIV infection ». HIV Infection and Immunosuppressive Disorders 13, no 3 (24 octobre 2021) : 81–95. http://dx.doi.org/10.22328/2077-9828-2021-13-3-81-95.
Texte intégralShrader, Hannah, Sabrina Helmold Hait, Sarah Lovelace, Meaghan Kilner, Chen-Hsiang Shen, Emily Coates, Martin Gaudinski et al. « Phenotypic analysis of HIV-1 resistance to CD4 binding site broadly-neutralizing antibodies ». Journal of Immunology 210, no 1_Supplement (1 mai 2023) : 223.08. http://dx.doi.org/10.4049/jimmunol.210.supp.223.08.
Texte intégralSteichen, Jon M., Ying-Cing Lin, Colin Havenar-Daughton, Simone Pecetta, Gabriel Ozorowski, Jordan R. Willis, Laura Toy et al. « A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses ». Science 366, no 6470 (31 octobre 2019) : eaax4380. http://dx.doi.org/10.1126/science.aax4380.
Texte intégralThavarajah, Jannifer Jasmin, Bo Langhoff Hønge et Christian Morberg Wejse. « The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention ». Viruses 16, no 6 (4 juin 2024) : 911. http://dx.doi.org/10.3390/v16060911.
Texte intégralKumar, Rajesh, Huma Qureshi, Suprit Deshpande et Jayanta Bhattacharya. « Broadly neutralizing antibodies in HIV-1 treatment and prevention ». Therapeutic Advances in Vaccines and Immunotherapy 6, no 4 (août 2018) : 61–68. http://dx.doi.org/10.1177/2515135518800689.
Texte intégralXu, Ling, Amarendra Pegu, Ercole Rao, Nicole Doria-Rose, Jochen Beninga, Krisha McKee, Dana M. Lord et al. « Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques ». Science 358, no 6359 (20 septembre 2017) : 85–90. http://dx.doi.org/10.1126/science.aan8630.
Texte intégralThèses sur le sujet "Broadly neutralizing antibodies (bNAbs)"
Nemoz, Benjamin. « Exploration longitudinale à haut débit et en cellule unique du répertoire d'anticorps neutralisants à large spectre chez un neutraliseur d'élite du VIH-1 ». Electronic Thesis or Diss., Université Grenoble Alpes, 2024. http://www.theses.fr/2024GRALV012.
Texte intégralHuman Immunodeficiency Virus type 1 (HIV-1) infection remains a major global health concern, with an estimated 37.7 million people living with the virus worldwide and new contaminations above a million cases yearly. Efficient anti-retroviral therapies are available, allowing a sustained relief for infected individuals. These therapeutics have also contributed to a better prevention and helped curb the epidemic, notably in high-income countries. However, a vaccine is still highly awaited for controlling this epidemic, especially in lower-income regions and precarious settings.The protective role of neutralizing antibodies (NAbs) has been unequivocally demonstrated in both animal models of HIV infection and in human settings. Consequently, the development of a B-cell-based vaccine capable of eliciting antibodies (Abs) with the ability to neutralize the majority of circulating viruses, namely broadly NAbs (bNAbs), could be foreseen as an answer to the HIV pandemic.The investigation of bNAb development in HIV-1 elite neutralizers provides valuable insights to inform the design of such vaccines. To date, most of the undertaken studies have relied on conventional single B-cell FACS sorting to isolate bNAbs. In the present study, we have used the Chromium Single Cell Immune Profiling approach to conduct a high-throughput longitudinal single-cell exploration of the B-cell repertoire in an HIV-1 elite neutralizer. Importantly, this novel method enables the use of a much greater number of HIV envelope glycoprotein (Env) baits compared to regular FACS-based Ab isolation studies, providing a more comprehensive view of the anti-Env Ab repertoire. In addition, this approach yields a wealth of information on the nature of the specific Abs identified and the corresponding B-cells.The study enabled the uncovering of the sequence of 12,130 putative HIV Env specific Abs. Antibodies from 39 lineages were produced and tested for neutralization, revealing 21 distinct neutralizing lineages. The results thus demonstrated the ability of the method to explore large antigen-specific Ab repertoires from longitudinal samples. The neutralizing activity of Abs from four neutralizing lineages together recapitulated the serum activity of the donor, achieving neutralization against 62.4 % of a large predictive panel of 126 pseudoviruses. One of these neutralizing Ab lineages was shown to target the gp120 high-mannose patch supersite with great breadth and potency; Abs from this lineage were sensitive to the presence of a glycan in position N332. A single of those Abs achieved most of the neutralization breadth (51.1 %) with a high potency (mean IC50 of 91.1 ng.mL-1). This Ab exhibited a 23 AA-long CDRH3 and 20 % somatic hypermutation (SMH). The lineage showed continuous evolution over 6.5 years of maturation, with observed SHM rates ranging from 2.0 % to 30.6 % for the heavy chain, without any insertions or deletions.Conventional FACS-based sorting was previously used to isolate bNAbs from the same donor. In comparison, the single cell high-throughput approach made possible the isolation of orders of magnitude more Abs. Furthermore, the newly isolated NAbs were overall more potent and broader than those isolated previously, indicating the superiority of the novel method in recovering neutralizing lineages. Ongoing structural studies will elucidate the epitopes responsible for the broad neutralization observed in this donor. Together, the findings may help the design of reverse vaccine approaches, which show promise in the development of an effective AIDS vaccine
Derby, Nina Rafterman. « Designing immunogens to elicit broadly reactive neutralizing antibodies to the HIV envelope / ». Thesis, Connect to this title online ; UW restricted, 2007. http://hdl.handle.net/1773/9302.
Texte intégralPenn-Nicholson, Adam Garth. « Characterization and evaluation of approaches to elicit Broadly Reactive Neutralizing Antibodies against HIV-1 ». Case Western Reserve University School of Graduate Studies / OhioLINK, 2008. http://rave.ohiolink.edu/etdc/view?acc_num=case1205433621.
Texte intégralSuphaphiphat, Karunasinee. « Anti-viral immune response in the semen of cynomolgus macaques and inhibition of cell to cell transmission by broadly neutralizing antibodies in an SIV/SHIV model of infection SHIV162P3 transmission by semen 1 leukocytes is efficiently 2 inhibited by broadly neutralizing antibodies ». Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS599.
Texte intégralHIV-1 sexual transmission occurs mostly through contaminated semen, which contains both free virions and infected leukocytes. Moreover, factors in seminal plasma (SP) can influence both semen infectivity and host’s response. Therefore, we used the experimental model of Simian Immunodeficiency Virus (SIV) infection of macaques, to investigate semen cells infectivity and the antiviral immune responses and to evaluate the potency of broadly neutralizing antibodies (bNAbs) to block cell-to-cell virus transmission.In SIVmac251 infected cynomolgus macaques, we investigated SIV-specific innate and adaptive responses in semen, including CD8+ T cell response, humoral response and levels of cytokines, chemokines and growth factors. SIV infection induced pro-inflammatory and immunoregulatory cytokines in semen and a concomitant upregulation of activated CD69+ CD8+ T cells and CCR5+ CXCR3+ CD8+ T cells. Neither SIV-specific CD8+ T-cell responses nor humoral responses controlled seminal viral shedding. Failure to control viral replication in SIV-infected semen is related to a general inflammation and immune activation, which possibly mirrors what happen in the male genital tract and which could lead to enhanced HIV/SIV transmission.Moreover, we developed cell-to-cell transmission assays, using either TZM-bl or human PBMC as target cells and SHIV162P3-infected splenocytes and CD45+ semen leukocytes as donor cells, and evaluated bNAbs-mediated inhibition. The bNAb panel included four 1st generation bNAbs and eight 2nd generation bNAbs. A combination of 1st generation bNAbs (2F5+2G12+4E10) was able to efficiently inhibit CAV transmission, while double combination or single bNAbs showed reduced potency. Of note, individual 2nd generation bNAbs inhibited transmission as efficiently as bNAbs combinations. An anti-V3 bNAb has been selected to evaluate its potential to block cell-to-cell transmission in vivo
Corti, Davide. « Analysis of the human B cell memory repertoire against infectious pathogens and isolation of broadly neutralizing human monoclonal antibodies / ». Bern : [s.n.], 2008. http://www.ub.unibe.ch/content/bibliotheken_sammlungen/sondersammlungen/dissen_bestellformular/index_ger.html.
Texte intégralYuan, Tingting, et 袁婷婷. « Identification of intermediate antibodies of broadly neutralizing HIV-1 human monoclonal antibody b12 and characterization of variable loops of HIV-1 envelop glycoprotein ». Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2013. http://hdl.handle.net/10722/196445.
Texte intégralGardner, Matthew Ryan. « Targeting the CD4- and Coreceptor-Binding Sites of the HIV-1 Envelope Glycoprotein ». Thesis, Harvard University, 2014. http://dissertations.umi.com/gsas.harvard:11644.
Texte intégralCheng, Yuxing. « Elicitation of antibody responses against the HIV-1 gp41 Membrane Proximal External Region (MPER) ». Thesis, Harvard University, 2014. http://dissertations.umi.com/gsas.harvard:11427.
Texte intégralMiles, Brodie, Shannon M. Miller et Elizabeth Connick. « CD4 T Follicular Helper and Regulatory Cell Dynamics and Function in HIV Infection ». FRONTIERS MEDIA SA, 2016. http://hdl.handle.net/10150/622733.
Texte intégralHashem, Anwar. « Targeting the Highly Conserved Sequences in Influenza A Virus ». Thèse, Université d'Ottawa / University of Ottawa, 2013. http://hdl.handle.net/10393/24058.
Texte intégralLivres sur le sujet "Broadly neutralizing antibodies (bNAbs)"
Cox, Josephine H., Stuart Z. Shapiro, Liza Dawson, Cynthia Geppert, Andrew M. Siegel et M. Patricia D’Souza. Vaccines for The Prevention and Treatment of HIV Infection. Sous la direction de Mary Ann Cohen, Jack M. Gorman, Jeffrey M. Jacobson, Paul Volberding et Scott Letendre. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199392742.003.0032.
Texte intégralSchommers, Philipp, Harry Gristick, Marit J. Van Gils et Kshitij Wagh, dir. Novel Concepts in Using Broadly Neutralizing Antibodies for HIV-1 Treatment and Prevention. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-88974-305-6.
Texte intégralChapitres de livres sur le sujet "Broadly neutralizing antibodies (bNAbs)"
Wu, Xueling. « HIV Broadly Neutralizing Antibodies : VRC01 and Beyond ». Dans HIV Vaccines and Cure, 53–72. Singapore : Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-13-0484-2_3.
Texte intégralZhou, Tongqing, et Kai Xu. « Structural Features of Broadly Neutralizing Antibodies and Rational Design of Vaccine ». Dans HIV Vaccines and Cure, 73–95. Singapore : Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-13-0484-2_4.
Texte intégralPauthner, Matthias G., et Lars Hangartner. « Broadly Neutralizing Antibodies to Highly Antigenically Variable Viruses as Templates for Vaccine Design ». Dans Current Topics in Microbiology and Immunology, 31–87. Cham : Springer International Publishing, 2020. http://dx.doi.org/10.1007/82_2020_221.
Texte intégralZhang, Mei-Yun, et Dimiter S. Dimitrov. « Sequential Antigen Panning for Selection of Broadly Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies ». Dans Methods in Molecular Biology, 143–54. Totowa, NJ : Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-302-2_11.
Texte intégralVan Regenmortel, Marc H. V. « Why Does the Molecular Structure of Broadly Neutralizing Monoclonal Antibodies Isolated from Individuals Infected with HIV-1 Not Inform the Rational Design of an HIV-1 Vaccine ? » Dans HIV/AIDS : Immunochemistry, Reductionism and Vaccine Design, 221–28. Cham : Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-32459-9_19.
Texte intégralMorris, L., et T. A. Moody. « Broadly Neutralizing Antibodies ». Dans Human Vaccines, 3–21. Elsevier, 2017. http://dx.doi.org/10.1016/b978-0-12-802302-0.00012-1.
Texte intégralMohamed, Yehia. « The Future of HIV Vaccine Development, Learned Lessons from COVID-19 Pandemic ». Dans New Topics in Vaccine Development [Working Title]. IntechOpen, 2024. http://dx.doi.org/10.5772/intechopen.114355.
Texte intégralNi, Fengyun, et Qinghua Wang. « Stem-specific Broadly Neutralizing Antibodies of Influenza Virus Hemagglutinin ». Dans Influenza : Current Research, 1–16. Caister Academic Press, 2016. http://dx.doi.org/10.21775/9781910190432.01.
Texte intégralHaynes, Barton F., Kevin O. Saunders, Garnett Kelsoe, John R. Mascola et Gary J. Nabel. « The Cellular and Molecular Biology of HIV-1 Broadly Neutralizing Antibodies ». Dans Molecular Biology of B Cells, 441–61. Elsevier, 2015. http://dx.doi.org/10.1016/b978-0-12-397933-9.00024-2.
Texte intégralMallard, Bonnie, Mehdi Emam, Shannon Cartwright, Tess Altvater-Hughes, Alexandra Livernois, Lauri Wagter-Lesperance, Douglas C. Hodgins et al. « Advances in understanding immune response in dairy cattle ». Dans Improving dairy herd health Improving, 121–62. Burleigh Dodds Science Publishing, 2021. http://dx.doi.org/10.19103/as.2020.0086.06.
Texte intégralActes de conférences sur le sujet "Broadly neutralizing antibodies (bNAbs)"
Morton, Scott P., et Joshua L. Phillips. « pH Dependent Binding Energies of Broadly Neutralizing Antibodies ». Dans 2021 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). IEEE, 2021. http://dx.doi.org/10.1109/bibm52615.2021.9669511.
Texte intégralSolodkov, P. P., T. N. Belovezhets, A. N. Chikaev, K. O. Baranov, S. V. Kulemzin, A. A. Gorchakov, S. V. Guselnikov et al. « SINGLE DOMAIN LLAMA ANTIBODIES BROADLY NEUTRALIZING SARS-COV-2 VARIANTS ». Dans X Международная конференция молодых ученых : биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-127.
Texte intégralFlyak, Andrew I., Stormy Ruiz, Michelle Colbert, Tiffany Luong, James E. Crowe, Justin R. Bailey et Pamela J. Bjorkman. « Abstract B109 : Broadly neutralizing antibodies against HCV use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design ». Dans Abstracts : Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference : Translating Science into Survival ; September 30 - October 3, 2018 ; New York, NY. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/2326-6074.cricimteatiaacr18-b109.
Texte intégral